U.S. markets closed
  • S&P Futures

    4,397.75
    +3.25 (+0.07%)
     
  • Dow Futures

    34,986.00
    +33.00 (+0.09%)
     
  • Nasdaq Futures

    14,941.25
    -6.50 (-0.04%)
     
  • Russell 2000 Futures

    2,194.80
    +8.10 (+0.37%)
     
  • Crude Oil

    72.01
    +0.36 (+0.50%)
     
  • Gold

    1,798.60
    -1.20 (-0.07%)
     
  • Silver

    24.74
    +0.09 (+0.35%)
     
  • EUR/USD

    1.1823
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3883
    +0.0005 (+0.03%)
     
  • USD/JPY

    109.8700
    +0.1030 (+0.09%)
     
  • BTC-USD

    39,233.41
    +1,865.83 (+4.99%)
     
  • CMC Crypto 200

    922.50
    +46.27 (+5.28%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,769.78
    -200.44 (-0.72%)
     

Global Epidermolysis Bullosa Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

·2 min read

DUBLIN, July 21, 2021--(BUSINESS WIRE)--The "Global Epidermolysis Bullosa Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Epidermolysis Bullosa Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Epidermolysis Bullosa market.

It covers emerging therapies for Epidermolysis Bullosa in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Epidermolysis Bullosa pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Epidermolysis Bullosa pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Epidermolysis Bullosa pipeline products by the company.

Short-term Launch Highlights:

Find out which Epidermolysis Bullosa pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Epidermolysis Bullosa phase 3 clinical trial pipeline products

  • Epidermolysis Bullosa phase 2 clinical trial pipeline products

  • Epidermolysis Bullosa phase 1 clinical trial pipeline products

  • Epidermolysis Bullosa preclinical research pipeline products

  • Epidermolysis Bullosa discovery stage pipeline products

  • Epidermolysis Bullosa pipeline products short-term launch highlights

Countries Covered

  • Global

  • Europe

  • US

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/m25wgq

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005665/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900